Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AA65 | ISIN: FR0013030152 | Ticker-Symbol: LFX
Tradegate
20.01.25
09:30 Uhr
23,650 Euro
+1,250
+5,58 %
Branche
Öl/Gas
Aktienmarkt
Sonstige
1-Jahres-Chart
FRANCAISE ENERGIE Chart 1 Jahr
5-Tage-Chart
FRANCAISE ENERGIE 5-Tage-Chart
RealtimeGeldBriefZeit
22,30022,40015:40
22,20022,50015:37
Actusnews Wire
608 Leser
Artikel bewerten:
(2)

LA FRANCAISE DE L'ENERGIE: FDE holds now 3.31% of its own shares through its share buyback program

Finanznachrichten News

FDE holds now 3.31% of its own shares through its share buyback program

Pontpierre, France, July 11th, 2024 - FDE (Euronext: FDE - ISIN: FR0013030152), a carbon negative energy producer, announces that it has bought back during the period of 1st July to 5th July 2024, 18,681 of its shares.

As FDE is currently in a negative period window, it will resume the share buyback program at the end of July, in accordance with the delegation of authority adopted by the Annual General Meeting of Shareholders of November 30th, 2023.

Aggregated presentation:

Name of issuerCode Issuer identifierDay of transaction Financial instrument identifier codeTotal daily volume (number of shares)Weighted average daily share acquisition priceMarket
La Française de l'Energie96950085A13FFW45G76501/07/2024FR001303015256530,31XPAR
La Française de l'Energie96950085A13FFW45G76502/07/2024FR001303015213129,35AQEU
La Française de l'Energie96950085A13FFW45G76502/07/2024FR00130301527529,35CEUX
La Française de l'Energie96950085A13FFW45G76502/07/2024FR0013030152429,35GSEI
La Française de l'Energie96950085A13FFW45G76502/07/2024FR00130301523 91229,4SGMU
La Française de l'Energie96950085A13FFW45G76502/07/2024FR00130301523 58529,35XPAR
La Française de l'Energie96950085A13FFW45G76503/07/2024FR00130301521 16630,19XPAR
La Française de l'Energie96950085A13FFW45G76504/07/2024FR001303015240031,09XPAR
La Française de l'Energie96950085A13FFW45G76505/07/2024FR00130301528 84331,99XPAR

Following these transactions, FDE holds 3.31% of its capital (excluding its own shares held under the liquidity contract).

This transaction is fully financed with available cash and will not affect the financial capacity of the group, still focused on the implementation of its various organic and external growth projects.

FDE's FY 2030 objectives comprise a nnual revenues of more than €175 million, and an EBITDA above €85 million, combined with over 20 million tons of CO2eq emissions avoided per annum

Next event:

Annual Sales 2024, 23 July 2024

Reuters code: FDE.PA Bloomberg code: FDE.FP
Press
contact@francaisedelenergie.fr
+ 33 3 87 04 34 51
Investor Relations
ir@francaisedelenergie.fr
+ 33 3 87 04 34 51

About La Française de l'Énergie

FDE is an independent multi-energy producer dedicated to making Net Zero happen.

As a specialist in local energy systems and the circular economy, FDE capitalizes on its industrial know-how ranging from engineering, energy production to CO2 storage to provide energy solutions that combine carbon footprint reduction with better resilience of the associated eco-systems.

For more information, visit https://www.francaisedelenergie.fr/

Disclaimer

This press release contains certain forward - looking statements and estimates concerning LFDE's financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words such as "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "plan," "potential," "predict," "objective," "should," or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management's current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company's control. Consequently, the actual results, financial condition, performances and/or achievements of LFDE or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and LFDE undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.

------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: yW1wk8WaZpiZm2ltlpVqbmpob5uTxZKca2Sex2OdaZ7GnZxhnGhhb8jGZnFnnWVq
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-86804-cp-110724-share-buyback_uk.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2024 Actusnews Wire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.